<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00863980</url>
  </required_header>
  <id_info>
    <org_study_id>C-486</org_study_id>
    <secondary_id>UMIN000001762</secondary_id>
    <nct_id>NCT00863980</nct_id>
  </id_info>
  <brief_title>Effects of Telmisartan on Ischemic Cardiovascular Events in High-risk Hypertensive Patients</brief_title>
  <acronym>KCPS</acronym>
  <official_title>Effects of Telmisartan Compared With Candesartan on Ischemic Cardiovascular Events in High-risk Hypertensive Patients: a Multi-center, Prospective, Randomized, Open-labeled, Blinded Endpoints Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kyoto Prefectural University of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kyoto Prefectural University of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is aimed to investigate whether treatment with Telmisartan is more effective than
      Candesartan in reducing the ischemic cardiovascular events in high-risk patients with
      cardiovascular disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is aimed to investigate whether treatment with Telmisartan is more effective than
      Candesartan in reducing the ischemic cardiovascular events in high-risk patients with
      cardiovascular disease.

      Study design: PROBE(Prospective, Randomized, Open-labeled Blind Endpoints)
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Principle investigator resigned in 2013
  </why_stopped>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>New or recurrent acute myocardial infarction and angina pectoris</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>All causes of mortality, cardiovascular death, new or recurrent stroke or peripheral artery diseases, new occurrence of diabetes mellitus</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1500</enrollment>
  <condition>Acute Myocardial Infarction</condition>
  <condition>Angina Pectoris</condition>
  <condition>Myocardial Ischemia</condition>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Hypertension</condition>
  <arm_group>
    <arm_group_label>Telmisartan</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment with Telmisartan</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Candesartan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with Candesartan</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Micardis (Telmisartan)</intervention_name>
    <description>40-80 mg/day oral administration</description>
    <arm_group_label>Telmisartan</arm_group_label>
    <other_name>21600AMZ00541000</other_name>
    <other_name>Micardis Tablets 40mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Blopress (Candesartan)</intervention_name>
    <description>8-12 mg/day oral administration</description>
    <arm_group_label>Candesartan</arm_group_label>
    <other_name>Blopless Tablets</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        The inclusion criteria are set by at least one of the three following risk factors:

          1. Coronary artery disease documented by at least one of the following:

               -  Myocardial infarction at least 12 months before enrollment and not planned for
                  percutaneous coronary intervention (PCI) or coronary artery bypass grafting
                  (CABG)

               -  Angina pectoris or asymptomatic myocardial ischemia undergoing percutaneous
                  coronary intervention (PCI) or coronary artery bypass grafting (CABG) at least 12
                  months before enrollment and not planned for further percutaneous coronary
                  intervention (PCI) or coronary artery bypass grafting (CABG)

          2. Peripheral arterial disease undergoing percutaneous transluminal angioplasty (PTA) or
             peripheral artery bypass grafting at least 6 months before enrollment

          3. Symptomatic cerebral infarction or cerebral hemorrhage at least 6 months before
             enrollment

        Exclusion Criteria:

        The exclusion criteria are set as follows:

          1. History of worsening of heart failure within the preceding 6 months

          2. Planned elective percutaneous coronary intervention (PCI) or coronary artery bypass
             grafting (CABG) within the anteceding 3 months

          3. History of myocardial infarction, unstable angina pectoris, percutaneous coronary
             intervention (PCI) or coronary artery bypass grafting (CABG) within the preceding 12
             months

          4. History of percutaneous hind limb angioplasty (PTA) or bypass grafting within the
             preceding 6 months

          5. History of cerebral infarction, cerebral hemorrhage within the past 6 months

          6. Congenital heart disease

          7. Uncontrolled hypertension on treatment (eg, BP&gt;180/110 mmHg)

          8. Pregnant women or women of childbearing potential

          9. Hepatic dysfunction (AST or ALT &gt;100IU/L)

         10. Renal impairment (serum creatinine level &gt;2.0 mg per 100 ml)

         11. Known hypersensitivity or intolerance to ARB
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hiroaki Matsubara, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Kyoto Prefectural University of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shakaihoken Kobe Central Hospital</name>
      <address>
        <city>Kobe</city>
        <zip>651-1145</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akashi Municipal Hospital</name>
      <address>
        <city>Kobe</city>
        <zip>673-8501</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kouseikai Takeda Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>600-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aijyukai Dohjin Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>602-0917</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto Second Red Cross Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>602-8026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto Prefectural University of Medicine</name>
      <address>
        <city>Kyoto</city>
        <zip>602-8566</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Social Insurance Kyoto Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>603-8151</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto Kojyo Hokenkai</name>
      <address>
        <city>Kyoto</city>
        <zip>604-8472</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto City Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>604-8845</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto First Red Cross Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>605-0981</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aiseikai Yamashina Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>607-8086</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tanabe Central Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>610-0334</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rakusai Simizu Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>610-1106</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uji Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>611-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto Yawata Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>614-8114</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seizinkai Simizu Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>615-8237</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Kyoto Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>617-0814</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Public Yamasiro Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>619-0214</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gakkentoshi Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>619-0238</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fukuchiyama City Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>620-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ayabe City Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>623-0011</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maizuru Red Cross Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>624-0906</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Hospital Organization Maizuru Medical Center</name>
      <address>
        <city>Kyoto</city>
        <zip>625-8502</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maizuru Kyosai Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>625-8585</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Public Nantan Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>629-0197</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto Prefectural Yosanoumi Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>629-2261</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kumihama Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>629-3403</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sakurakai Takahashi Hospital</name>
      <address>
        <city>Kyoto</city>
        <zip>654-0026</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yuuseikai Midorigaoka Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>569-1121</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Matsushita Memorial Hospital</name>
      <address>
        <city>Osaka</city>
        <zip>570-8540</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Shiga Hospital</name>
      <address>
        <city>Shiga</city>
        <zip>520-3046</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omihachiman Community Medical Center</name>
      <address>
        <city>Shiga</city>
        <zip>523-0892</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 17, 2009</study_first_submitted>
  <study_first_submitted_qc>March 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 18, 2009</study_first_posted>
  <last_update_submitted>September 1, 2015</last_update_submitted>
  <last_update_submitted_qc>September 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kyoto Prefectural University of Medicine</investigator_affiliation>
    <investigator_full_name>Hiroyuki Yamada</investigator_full_name>
    <investigator_title>Department of Cardiovascular Medicine</investigator_title>
  </responsible_party>
  <keyword>angiotensin</keyword>
  <keyword>receptor</keyword>
  <keyword>vulnerable plaque</keyword>
  <keyword>coronary artery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Angina Pectoris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Candesartan</mesh_term>
    <mesh_term>Candesartan cilexetil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

